Whalesbook
The directive to "Build more, produce more, connect more, and export more" from Prime Minister Narendra Modi sets an ambitious trajectory for India's Micro, Small, and Medium Enterprises (MSMEs) and its broader industrial sector. This call to action, delivered during a post-Budget webinar focused on economic sustainability, emphasizes the interconnectedness of manufacturing, logistics, and MSMEs as fundamental economic pillars. The underlying objective is to position India as a robust and reliable manufacturing partner within the evolving global supply chain architecture.
Global Realignment Tailwinds
India is strategically positioned to capitalize on the ongoing global supply chain realignment, often referred to as the "China Plus One" strategy. Geopolitical shifts and a global emphasis on resilience over absolute cost optimization are compelling multinational corporations to diversify manufacturing away from single-country dependencies. This creates a substantial window of opportunity for India to attract foreign direct investment and deepen its integration into global value chains. Government initiatives, such as the Production-Linked Incentive (PLI) schemes, are specifically designed to stimulate capacity expansion in key sectors including electronics, pharmaceuticals, and automobiles. [4, 5, 16, 17] Furthermore, India's substantial domestic market provides a critical foundation, underwriting production scale and offering manufacturers a captive demand base even amidst external market volatility. [16]
The MSME Bottlenecks
Despite the strategic impetus and favorable global tailwinds, the path for Indian MSMEs to achieve this export surge is impeded by significant structural challenges. A critical area of concern is research and development (R&D) investment. India's Gross Expenditure on R&D (GERD) as a percentage of GDP remains stagnant at approximately 0.6-0.7%, a fraction of what global benchmarks like the US (over 2.8%) and China (2.4%) invest annually. [23, 27, 33] The private sector's contribution to GERD in India, at around 36%, is alarmingly low compared to China's 75% and the US's 68%, indicating a dire lack of industry-led innovation essential for graduating to higher-value product segments. [23]
Logistics costs in India, estimated at a burdensome 13-14% of GDP, significantly erode competitiveness, punishing MSMEs operating on razor-thin margins. [10] This inefficiency is exacerbated by inadequate infrastructure and last-mile connectivity, leading to predictable transit delays and inflated operational expenses. [11] Furthermore, India confronts intense competition from agile economies like Vietnam. Vietnam's export growth has historically surged past India's, with its manufacturing sector deeply entrenched in global value chains, particularly in electronics and apparel. [35, 36, 37] Vietnam also benefits from a more attractive corporate tax environment and a wider network of free trade agreements, conferring distinct advantages. [36, 37] The stark reality is that only about 10% of Indian MSMEs currently export, a figure dwarfed by nearly 40% in comparable economies, indicating a fundamental weakness in market penetration and export readiness. [11] Persistent issues plague the sector: labyrinthine export documentation, restricted access to affordable finance, and a failure to meet stringent global quality and certification standards, with over 63% of MSMEs lacking crucial ISO certifications. [6, 21]
The Indian market itself, while growing, exhibits high valuations. The Sensex P/E ratio stood at 23.4 in November 2025, suggesting that equity markets are generally expensive, which can complicate capital access for smaller enterprises. [26]
Biopharma SHAKTI: A High-Value Niche
A specific initiative, the Biopharma SHAKTI Mission, targets a crucial high-value segment, aiming to transform India into a global center for biologics and advanced therapies with an aspiration to capture 5% of the global market share. [7, 8] This represents a strategic move towards higher-value, innovation-driven pharmaceutical products, signaling a shift beyond generics. [9] The approximately ₹10,000 crore program intends to strengthen the domestic ecosystem for biologics and biosimilars, reduce import dependence, and enhance overall competitiveness within this specialized sector. [8] Its success, however, will be heavily contingent on the broader improvement of India's R&D capabilities, regulatory environment, and the sector's ability to scale manufacturing efficiently. [9, 20]
The Path to Competitiveness
Achieving the Prime Minister's export ambitions necessitates a sustained and multi-pronged approach that tackles systemic weaknesses. Increasing R&D investment, particularly from the private sector, and fostering robust industry-academia collaboration are paramount for innovation. Streamlining logistics through infrastructure development is critical to reducing costs and improving transit times. Enhanced access to affordable finance and simplified compliance procedures are essential to equip MSMEs for effective global competition. Furthermore, a strategic recalibration of trade policies, potentially including deeper engagement with multilateral agreements, could bolster market access and competitiveness against nations like Vietnam. Without decisive action on these core systemic issues, the aspiration of significantly boosting India's exports via its MSME sector risks remaining largely aspirational.